Catheter Precision, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David A. Jenkins
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1670 Highway 160 West Fort Mill SC United States of America 29708
- IPO Date
- Sep 27, 2018
- CIK
- 0001716621
- Website
- catheterprecision.com
- Similar Companies
- Business
- Catheter Precision, Inc. designs, manufactures, and sells advanced medical devices focused on the cardiac electrophysiology market. Its core products include the VIVO™ non-invasive 3D cardiac mapping system that aids in localizing the origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts, and the LockeT suture retention device, which facilitates secure suture retention and removal in clinical settings. The company’s proprietary MAMMOTH™ electrophysiology catheter system offers real-time 3D visualization of the catheter tip, enhancing precision and safety during cardiac procedures. Catheter Precision targets healthcare providers and institutions specializing in cardiac care, operating primarily in the United States with expanding presence in international markets including Central and Eastern Europe. Founded in 2002 and headquartered in Fort Mill, South Carolina, Catheter Precision recently secured a significant tender with Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary, marking a strategic expansion into Central European markets. It has also received first purchase orders from hospitals in Croatia and increased orders within the U.S., notably from Eisenhower Medical Center, UCLA Medical Center, and Rady Children’s Hospital in California, supporting the national launch of its LockeT device. The company completed the acquisition of Cardionomic’s heart failure assets, which includes the CPNS system targeting heart failure treatment. These developments underscore Catheter Precision’s focus on broadening its product portfolio while growing its commercial footprint and clinical team internationally. Catheter Precision operates within the medical device industry, specifically in electrophysiology and cardiac intervention segments. It emphasizes innovation, safety, and efficiency in its technologies designed to improve patient outcomes in cardiac arrhythmia interventions. The company is publicly listed on the NYSE American exchange under the ticker VTAK and maintains a workforce of approximately 20-50 employees. Its strategic initiatives in the last 1-2 years include product launches, expanded sales and clinical teams, international tender wins, and targeted acquisitions to enhance its offerings and market reach. This comprehensive product and operational strategy positions Catheter Precision, Inc. as a growing player in the global cardiac electrophysiology device market with a commitment to delivering innovative solutions that advance the standard of patient care.
Aviation Stocks Lift Off: Flyte (VTAK) Teams Up with Blade Urban Air Mobility
Flyte Partners with Blade to Expand Vision Jet Distribution
Flyte Partners with LifeVac to Equip Every Vision Jet with Life-Saving Equipment
Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform
FLYTE EXPANDS STRATEGIC RELATIONSHIP WITH VOLATO BY JOINING VAUNT PLATFORM
Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)
Volato Group Announces $2.2 Million Strategic Investment and AI Infrastructure Acquisition Focus
FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND
FLYTE ACTIVATES HIGH-FREQUENCY PREAKNESS FLIGHT PROGRAM, DEPLOYING FLEET TO SERVE STRONG NORTHEAST DEMAND
Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel
Flyte Deploys Additional Vision Jets in the Northeast to Capture Surging Summer Demand
Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Expands By 91.9%
FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
New LockeT Data Accepted in Leading Electrophysiology Journal
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
Catheter Precision (VTAK) to Release Earnings on Friday
VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.
Catheter Precision's LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026
Catheter Precision Divests Non-Core Assets As It Shifts Focus
Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth